Criterium, Inc. joins with Hemostemix to Advance Clinical Trial Preparation
Hemostemix, a clinical-stage Canadian-Israeli company developing innovative blood-derived cell therapies for severe medical conditions, announced today the kick-off of a services collaboration with Criterium Inc. as its clinical research organization (CRO) for the company’s phase 2 clinical trial in critical limb ischemia.